iifl-logo

Ipca Laboratories Ltd Half Yearly Results

1,470.9
(1.90%)
Apr 23, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

4,447.53

4,085.87

3,619.17

3,057.63

3,186.69

Excise Duty

0

0

0

0

0

Net Sales

4,447.53

4,085.87

3,619.17

3,057.63

3,186.69

Other Operating Income

0

0

0

0

0

Other Income

46.87

41.37

83.4

67.28

58.34

Total Income

4,494.4

4,127.24

3,702.57

3,124.91

3,245.03

Total Expenditure

3,613.33

3,501.35

2,990.28

2,656.61

2,660.94

PBIDT

881.07

625.89

712.29

468.3

584.09

Interest

46.61

62.77

75.5

29.29

16.25

PBDT

834.46

563.12

636.79

439.01

567.84

Depreciation

199.24

197.63

159.61

136.11

125.45

Minority Interest Before NP

0

0

0

0

0

Tax

182.36

138.35

171.83

91.72

138.64

Deferred Tax

8.44

1.58

1.7

10.38

12.62

Reported Profit After Tax

444.42

225.56

303.65

200.8

291.13

Minority Interest After NP

23.17

-17.14

-7.29

3.5

4.17

Net Profit after Minority Interest

421.72

239.47

307.88

184.36

286.96

Extra-ordinary Items

0

-68.26

-25.13

0

0

Adjusted Profit After Extra-ordinary item

421.72

307.73

333.01

184.36

286.96

EPS (Unit Curr.)

16.62

9.44

12.14

7.27

11.31

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

200

0

200

0

400

Equity

25.37

25.37

25.37

25.37

25.37

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

19.81

15.31

19.68

15.31

18.32

PBDTM(%)

-

-

-

-

-

PATM(%)

9.99

5.52

8.39

6.56

9.13

Ipca Labs.: Related NEWS

Ipca Laboratories to Consolidate US Generics Business; Shares Up 1%
23 Sep 2024|03:01 PM

This consolidation aims to streamline all of Ipca Group's US generics formulations under a single entity, enhancing operational efficiency.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.